ArticleHuman vaccines & immunotherapeutics2025
Long-term effectiveness of COVID-19 vaccination in preventing hospitalization among household contacts: A case-control study from December 2021 to April 2023.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to assess the long-term effect of Coronavirus disease 2019 (COVID-19) vaccination in improving infection, symptoms and disease severity more than 1 year. Consecutive adult inpatients diagnosed with COVID-19 through clinical criteria from two hospitals with household contacts were included. The exposure was COVID-19 vaccination. The primary outcome was hospitalization, while infection, symptoms, and pneumonia were assessed as exploratory outcomes. Multivariable logistic regression, subgroup and sensitivity analysis were conducted. From December 18, 2022, to April 7, 2023, 1,410 individuals were prospectively screened, and 1,047 individuals were included. The male proportion was 49.24% with the mean age of 66.10 years. A total of 883 (84.34%) participants were vaccinated with a median time of 297.5 (157.0, 389.0) days between the last vaccine and enrollment, and a median time of 446.5 (162.8, 504.8) days was found in fully vaccinated patients. The infection rate among unvaccinated patients was significantly higher (96.72% vs. 88.69%,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.